Evidence map›Paper›PMID 31343468›Full record

ArticleClinical and translational gastroenterology2019

Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis.

Andromachi Kotsafti, Renata DʼIncà, Melania Scarpa, Matteo Fassan, Imerio Angriman, Claudia Mescoli, Nicolò Bortoli, Paola Brun, Romeo Bardini, Massimo Rugge and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Andromachi KotsaftiLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Renata DʼIncàGastroenterology Unit, Azienda Ospedaliera di Padova, Padova, Italy.
Melania ScarpaLaboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Matteo FassanDepartment of Medicine, University of Padova, Padova, Italy.
Imerio AngrimanDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Claudia MescoliDepartment of Medicine, University of Padova, Padova, Italy.
Nicolò BortoliDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Paola BrunDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Romeo BardiniDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Massimo RuggeDepartment of Medicine, University of Padova, Padova, Italy.
Edoardo SavarinoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Fabiana ZingoneDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Carlo CastoroUpper GI Surgery Unit, Istituto Humanitas, Rozzano, Italy.
Ignazio CastagliuoloDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Marco ScarpaGeneral Surgery Unit, Azienda Ospedaliera di Padova, Padova, Italy.
University of Padua · ITAzienda Ospedaliera di Padova · ITFondazione Humanitas per la Ricerca · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn patients with ulcerative colitis (UC), dysplasia develops in 10%-20% of cases. The persistence of low-grade dysplasia (LGD) in UC in 2 consecutive observations is still an indication for restorative proctocolectomy. Our hypothesis is that in the case of weak cytotoxic activation, dysplasia persists. We aimed to identify possible immunological markers of LGD presence and persistence.

methodsWe prospectively enrolled 112 UC patients who underwent screening colonoscopy (T0) who had biopsies taken from their sigmoid colon. Ninety of them had at least a second colonoscopy (T1) with biopsies taken in the sigmoid colon and 8 patients had dysplasia in both examinations suggesting a persistence of LGD in their colon. Immunohistochemistry and real time polymerase chain reaction for CD4, CD69, CD107, and CD8β messenger RNA (mRNA) expression and flow cytometry for epithelial cells expressing CD80 or HLA avidin-biotin complex were performed. Non-parametric statistics, receiver operating characteristic curves analysis, and logistic multiple regression analysis were used.

resultsThirteen patients had LGD diagnosed at T0. The mucosal mRNA expression of CD4, CD69, and CD8β was significantly lower than in patients without dysplasia (P = 0.033, P = 0.046 and P = 0.007, respectively). A second colonoscopy was performed in 90 patients after a median follow-up of 17 (12-25) months and 14 of the patients were diagnosed with LGD. In these patients, CD8β mRNA expression at T0 was significantly lower in patients without dysplasia (P = 0.004). A multivariate survival analysis in a model including CD8β mRNA levels and age >50 demonstrated that both items were independent predictors of dysplasia at follow-up (hazard ratio [HR] = 0.47 [95% confidence interval [CI]: 0.26-0.86], P = 0.014, and HR = 13.32 [95% CI: 1.72-102.92], P = 0.013). DISCUSSION: These data suggest a low cytotoxic T cell activation in the colonic mucosa of UC patients who do not manage to clear dysplasia. Thus, low level of CD8β mRNA expression in non-dysplastic colonic mucosa might be considered in future studies about the decision making of management of LGD in UC.

Indexed as

AdultAntigens, CDAntigens, Differentiation, T-LymphocyteB7-1 AntigenBiopsyCD4 AntigensCD69 AntigensCD8 AntigensColitis, UlcerativeColonoscopyColon, SigmoidFemaleHumansHyperplasiaImmunohistochemistryIntestinal MucosaAntigens, CDAntigens, Differentiation, T-LymphocyteB7-1 AntigenCD4 AntigensCD69 AntigensCD8 AntigensCD8beta antigenLectins, C-TypeLysosomal-Associated Membrane Protein 1Lysosomal-Associated Membrane Protein 2RNA, Messenger

Identifiers

PMID31343468
PMCPMC6708661
OpenAlexW2963133730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.